Clinical Trial News and Research

RSS

Isotechnika fourth quarter consolidated net loss increases to $2.42 million

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2010 and provided a review of the Company's operational and financial progress for 2010 and to the current date.

25 Mar 2011

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program.

25 Mar 2011

Tengion 2010 adjusted net loss decreases to $25.8 million

Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.

25 Mar 2011

'Consent rituals' cause life-threatening delays

Current rules requiring researchers to obtain consent for patients to take part in clinical trials in emergency situations are causing life-threatening delays to treatment, experts have argued.

25 Mar 2011

EU supports new collaborative research projects on tuberculosis

It's March 24th again and the World Tuberculosis Day reminds us that for almost 50 years no new drugs have been developed against this terrible disease, which is currently killing nearly two million people worldwide each year. It's a global problem because the emergence of drug resistant strains of this infectious disease - normally associated with poverty - is a growing problem even in high-income economies.

25 Mar 2011

Study: High intake of omega-3 fats can help prevent obesity-related chronic diseases

A study of Yup'ik Eskimos in Alaska, who on average consume 20 times more omega-3 fats from fish than people in the lower 48 states, suggests that a high intake of these fats helps prevent obesity-related chronic diseases such as diabetes and heart disease.

25 Mar 2011

First AngelMed Guardian cardiac monitor system implanted in patient at Jersey Shore

Today at Jersey Shore University Medical Center, 66-year-old heart attack survivor Charles Theodora from Ocean Township became the first NY/NJ Metropolitan resident to be implanted with the experimental AngelMed Guardian cardiac monitor and alert system device that could alert him if a heart attack is imminent.

25 Mar 2011

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that its specially formulated ischemic adult allogeneic mesenchymal stem cells have been successfully used to treat the first patient in an ischemic stroke study conducted at the University of California, San Diego.

25 Mar 2011

BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

25 Mar 2011

Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers

Oncolytics Biotech Inc. today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.

25 Mar 2011

Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

Christiana Care Health System's Helen F. Graham Cancer Center is leading a national clinical trial to determine if Crestor, a cholesterol-lowering drug, can prevent new colon tumors from forming after colon cancer surgery.

25 Mar 2011

Perceptive Informatics announces eClinical Product Suite survey results

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced results of a survey conducted during its recent webinar entitled "Designing and Delivering an eClinical Product Suite."

From Parexel 24 Mar 2011

New study: Coronary calcium scan can help reduce risk of heart disease

A new study of coronary artery calcium scanning - a simple, noninvasive test that gives patients baseline information about plaque in their coronary arteries—has shown that the scan helps them make heart-healthy lifestyle changes and lower their heart disease risk factors.

24 Mar 2011

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company has been selected to present key Tovaxin data at the upcoming American Academy of Neurology 63rd Annual Meeting to be held in Honolulu, Hawaii April 9-16, 2011.

24 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Gilead Sciences, Inc. today announced that the Phase III clinical trial of its investigational antiretroviral agent elvitegravir, a novel oral integrase inhibitor being evaluated for the treatment of HIV-1 infection in treatment-experienced patients, met its primary objective.

24 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.

23 Mar 2011

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.

23 Mar 2011

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

Nordion Inc., a leading provider of products and services to the global health science market, today announced that it has received U.S. Food and Drug Administration approval to conduct a Phase III clinical trial for TheraSphere® under an Investigational Device Exemption.

23 Mar 2011

Clinical Trial News and Research

Isotechnika fourth quarter consolidated net loss increases to $2.42 million

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Tengion 2010 adjusted net loss decreases to $25.8 million

'Consent rituals' cause life-threatening delays

EU supports new collaborative research projects on tuberculosis

Study: High intake of omega-3 fats can help prevent obesity-related chronic diseases

First AngelMed Guardian cardiac monitor system implanted in patient at Jersey Shore

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

BrainStorm provides review of recent accomplishments for shareholders, investors

Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers

Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

Perceptive Informatics announces eClinical Product Suite survey results

New study: Coronary calcium scan can help reduce risk of heart disease

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

KaloBios commences KB004 Phase 1 trial in patients with leukemia

Cilag, POZEN enter license agreement to develop and commercialize MT 400

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer